PMV Pharmaceuticals, Inc (PMVP) is a publicly traded Healthcare sector company. As of May 21, 2026, PMVP trades at $1.31 with a market cap of $66.66M and a P/E ratio of -0.88. PMVP moved +0.00% today. Year to date, PMVP is +7.38%; over the trailing twelve months it is +40.74%. Its 52-week range spans $0.81 to $1.88. Analyst consensus is strong buy with an average price target of $4.50. Rallies surfaces PMVP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PMV Pharmaceuticals Gains FDA ODD, Reports 44% ORR and $93.5M Cash: PMV Pharma reported $93.5 million in cash providing runway into Q2 2027, and net cash used was $19.7 million in Q1 2026 with an $18 million net loss. Rezatapopt received FDA Orphan Drug Designation for TP53 Y220C ovarian cancer and achieved a 44% overall response rate in Phase 2 PYNNACLE.
| Metric | Value |
|---|---|
| Price | $1.31 |
| Market Cap | $66.66M |
| P/E Ratio | -0.88 |
| EPS | $-1.49 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.88 |
| 52-Week Low | $0.81 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.38M |
| Net Income | $-78.34M |
| Gross Margin | 0.00% |
3 analysts cover PMVP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.50.